Mayo Clinic, 2bPrecise partners to establish genomics-based CDS tools

The Mayo Clinic will work with a precision medicine company to establish and research a genomics-based care protocols approach. The renowned delivery system has signed a license contract with 2bPrecise, a Pittsburgh-based company that gives an EHR-agnostic cloud-based precision medicine platform.

The partners will utilize the 2bPrecise platform and combine it with Mayo Clinic’s knowledge and electronic phenotyping algorithms to further establish clinical protocols, which will be incorporated into the platform.

Initial work will be utilized to apply research to measure outcomes in sufferers who have cardiovascular genetic disease.

The two agencies will start their collaboration by bringing Mayo Clinic's algorithm for FH into the 2bPrecise platform to derive insights from combined clinical and genomic research information. The collaboration targets to boost clinical researchers with the capability to test and validate new protocols based on clinical-genomic insights, with the ultimate aim of making these protocols available for optimized decision-making at the point of care.

The 2bPrecise platform harmonizes clinical and genomic data to extract patient-specific insights and present them in an actionable way to the clinician, within their present EHR workflow, overlaying knowledge sources to instruct and enable clinical genomics at point of care.

Executives of 2bPrecise claim that they selected Mayo Clinic for this work due to their strong subject matter expertise and work in the area of clinical genomics, particularly their research in familial hypercholesterolemia (FH), and for their desire to share their care algorithms more broadly with the medical community.

“Mayo Clinic has a very robust genomics research discipline,” claims Assaf Halevy, founder and CEO of 2bPrecise. “We’re excited to collaborate with premier agencies such as Mayo Clinic to advance genomic science and help make it clinically actionable.”

Mayo Clinic has a financial interest in the technology, with executives saying they plan to use any revenue it gets to support its not-for-profit mission in patient care, education and research.